- Home
- BBAI vs KNSA Comparison
BBAI vs KNSA Comparison
Compare BBAI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBAI | KNSA |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 3.4B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BBAI | KNSA |
|---|---|---|
| Price | $4.22 | $45.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 39.7M | 545.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $31.26 | $38.01 |
| Revenue Next Year | N/A | $17.42 |
| P/E Ratio | ★ N/A | $61.53 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $2.36 | $18.26 |
| 52 Week High | $9.39 | $49.12 |
Technical Indicators
Market Signals| Indicator | BBAI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 54.98 |
| Support Level | $3.66 | $40.47 |
| Resistance Level | $4.61 | $49.12 |
| Average True Range (ATR) | 0.29 | 2.18 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 73.35 | 60.63 |
Price Performance
Historical ComparisonAbout BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.